A brain organoid study reveals how a genetic mutation associated with Pitt-Hopkins syndrome, a profound form of autism, disrupts neural development. Using gene-editing technology, researchers recovered the function of the TCF4 gene and effectively restored neural structure and function.
A new ethical framework proposes researchers should already assume brain organoids already have consciousness, rather than waiting for research to confirm they do.
Brain organoids can be used to study molecular mechanisms that drive brain aging and neurodegenerative disorders. The mini-brains allow for the testing of molecules that could become potential therapeutic treatment options for neurodegenerative diseases.
Newly developed brain organoids grown from stem cells showed organized waves of neural activity similar to that seen in living human brains.
Researchers have developed a new brain organoid model to study the mechanistic causes of Alzheimer's disease and test dementia drugs currently in development.
Researchers recreated the damage seen in frontotemporal dementia in brain organoid models. The study reveals an experimental drug designed to treat Crohn's disease may help prevent neuron death associated with FTD.
Using human stem cells to develop a brain organoid model, researchers were able to show exposure to a common pesticide synergizes with an autism-linked gene mutation. The study provides clear evidence that genetics and environment may combine to disrupt neurodevelopment.
Brain organoids, or mini-brains, created from human stem cells appear to develop in much the same way as a human brain. The organoids follow an internal clock that guides their maturation in sync with the timeline for human brain development.
By altering the NOVA1 gene, researchers were able to "Neanderthal-izes" a brain organoid model. Study reveals there is only a one gene difference between the modern human brain and that of our extinct ancestors.